How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Clarkson University researchers have developed an artificial intelligence tool that can uncover the mathematical equations governing complex and chaotic systems directly from data. The technology, ...

Your institution does not have access to this book on JSTOR. Try searching on JSTOR for other items related to this book. https://doi.org/10.2307/j.ctvjnrt76.5 https ...

On March 21, 2026, at the Seaholm Power Plant in Austin, Elon Musk unveiled what he called "the most epic chip-building ...

On July 4, 2026, Vitalik Buterin published the most consequential Ethereum protocol document in four years: an updated "Lean Ethereum" strawmap that commits the world's second-largest blockchain to ...